» Articles » PMID: 36457592

Wenshen Yiqi Keli Mitigates the Proliferation and Migration of Cigarette Smoke Extract-Induced Human Airway Smooth Muscle Cells Through MiR-155/FoxO3a Axis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Some domestic scholars revealed the effectiveness of Wenshen Yiqi Keli (WSYQKL) on chronic obstructive pulmonary disease (COPD). However, the exact mechanism of WSYQKL on COPD is fuzzy and needs further research. We adopted UPLC-Q/TOF-MS to analyze the chemical components of WSYQKL. In experiments, human airway smooth muscle cells (hASMCs) were intervened with 2.5% cigarette smoke extract (CSE), medicine serum of WSYQKL, miR-155 mimic, and FoxO3a silencing. Cell viability, proliferation, migration, and the expressions of miR-155, PCNA, Ki67, p21, p27, and FoxO3a were examined by cell counting kit-8, EdU staining, Transwell assay, scarification assay, qRT-PCR, immunol cytochemistry, and western blot, respectively. The association between miR-155 and FoxO3a was assessed by database and luciferase reporter gene analysis. We identified 47 kinds of chemical compositions of WSYQKL in ESI mode and 42 kinds of components of WSYQKL in ESI mode. The medicine serum of WSYQKL strongly alleviated the proliferation and migration of hASMCs induced by CSE in a concentration-dependent manner. The medicine serum of WSYQKL enhanced the levels of p21, p27, and FoxO3a and weakened PCNA and Ki67 levels in hASMCs induced by CSE with the increase of concentration. MiR-155 mimic or FoxO3a silencing notably advanced CSE-treated HASMC viability, proliferation, migration, and the levels of PCNA and Ki67 and downregulated the levels of p21, p27, and FoxO3a in CSE-triggered hASMCs, which was reversed by WSYQKL-containing serum. Our results described that WSYQKL alleviated the proliferation and migration of hASMCs induced by CSE by modulating the miR-155/FoxO3a axis.

Citing Articles

Wenshen Yiqi Granule Alleviates Chronic Obstructive Pulmonary Disease via the Long Noncoding RNA-XIST/MicroRNA-200c-3p Axis.

Deng H, Zhu S, Yu F, Song X, Jin X, Ding X Pulm Circ. 2025; 15(1):e70040.

PMID: 39897408 PMC: 11783148. DOI: 10.1002/pul2.70040.

References
1.
Wu X, Chang S, Jin J, Gu W, Li S . NLRP3 inflammasome mediates chronic intermittent hypoxia-induced renal injury implication of the microRNA-155/FOXO3a signaling pathway. J Cell Physiol. 2018; 233(12):9404-9415. DOI: 10.1002/jcp.26784. View

2.
Naveed A, Ur-Rahman S, Abdullah S, Naveed M . A Concise Review of MicroRNA Exploring the Insights of MicroRNA Regulations in Bacterial, Viral and Metabolic Diseases. Mol Biotechnol. 2017; 59(11-12):518-529. DOI: 10.1007/s12033-017-0034-7. View

3.
Fazleen A, Wilkinson T . Early COPD: current evidence for diagnosis and management. Ther Adv Respir Dis. 2020; 14:1753466620942128. PMC: 7394029. DOI: 10.1177/1753466620942128. View

4.
De Smet E, Van Eeckhoutte H, Avila Cobos F, Blomme E, Verhamme F, Provoost S . The role of miR-155 in cigarette smoke-induced pulmonary inflammation and COPD. Mucosal Immunol. 2019; 13(3):423-436. DOI: 10.1038/s41385-019-0241-6. View

5.
Allen J . Airway function throughout the lifespan: Pediatric origins of adult respiratory disease. Pediatr Investig. 2020; 3(4):236-244. PMC: 7331336. DOI: 10.1002/ped4.12165. View